Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients

Yi Jen Chen, Chiou Chung Yuan, Kuan Chih Chow, Peng Hui Wang, Chiung Ru Lai, Ming Shyen Yen, Liang Shun Wang

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Objective. Results of a recent study on human ovarian cancer cell lines indicated that overexpression of dihydrodiol dehydrogenase (DDH) was associated with resistance to cisplatin and disease progression. We examined the relationships between DDH expression and chemotherapy resistance in ovarian cancer patients. Methods. Using immunohistochemistry, expression of DDH was measured in 41 patients with epithelial ovarian cancers. All patients underwent primary debulking surgery, followed with six cycles of cisplatin-based chemotherapy. Normal ovarian tissues were obtained from patients with benign gynecologic diseases (n = 14). Expression of DDH was confirmed by reverse transcription-polymerase chain reaction. The correlation between DDH expression and clinico-pathological parameters was analyzed by statistical analysis. Difference of progression-free survivals between different groups was compared by a log-rank test. Results. Eighteen ovarian cancer samples (43.9%) expressed DDH at a moderate to strong level. This marked a significant difference from the negligible expression (1/14, 7.1%) found in the control group (P = 0.02). Of interest, the clear cell adenocarcinoma revealed DDH overexpression (75%) and mucinous adenocarcinoma revealed low DDH expression (16.7%), although DDH expression did not show any significant variation according to different histotypes. DDH overexpression was found in a statistically significantly higher percentage of cisplatin-resistant cases (n = 8/11; 72.7%) than in cisplatin-sensitive cases (n = 9/27; 33.3%) (P = 0.037). Using multivariate analysis, only DDH retained as an independent role in predicting a poor chance of response to cisplatin-based treatment. DDH overexpression cases (median 12 months, 95% confidence interval 4-20) demonstrated a shorter progression-free survival than DDH-negative cases (median 28 months, 95% confidence interval 23-33), but this result did not reach the statistical significance (P = 0.1742). In the advance stage, the DDH-positive group has a shorter PFS as compared with DDH-negative group, and this result closely approaches the statistical significance (P = 0.0669). Conclusions. DDH is expressed in a high percentage of primary ovarian tumors and its expression may be associated with cisplatin-based chemotherapy resistance. The possible prognostic role of DDH in ovarian carcinoma deserves further study.

Original languageEnglish
Pages (from-to)110-117
Number of pages8
JournalGynecologic Oncology
Volume97
Issue number1
DOIs
Publication statusPublished - Apr 2005
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Cisplatin
Drug Therapy
trans-1,2-dihydrobenzene-1,2-diol dehydrogenase
Disease-Free Survival
Clear Cell Adenocarcinoma
Female Genital Diseases
Confidence Intervals
Mucinous Adenocarcinoma
Reverse Transcription
Disease Progression

Keywords

  • Chemotherapy resistance
  • Dihydrodiol dehydrogenase (DDH)
  • Ovarian cancer

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients. / Chen, Yi Jen; Yuan, Chiou Chung; Chow, Kuan Chih; Wang, Peng Hui; Lai, Chiung Ru; Yen, Ming Shyen; Wang, Liang Shun.

In: Gynecologic Oncology, Vol. 97, No. 1, 04.2005, p. 110-117.

Research output: Contribution to journalArticle

Chen, Yi Jen ; Yuan, Chiou Chung ; Chow, Kuan Chih ; Wang, Peng Hui ; Lai, Chiung Ru ; Yen, Ming Shyen ; Wang, Liang Shun. / Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients. In: Gynecologic Oncology. 2005 ; Vol. 97, No. 1. pp. 110-117.
@article{19a164057f9349109c1784761935c1ae,
title = "Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients",
abstract = "Objective. Results of a recent study on human ovarian cancer cell lines indicated that overexpression of dihydrodiol dehydrogenase (DDH) was associated with resistance to cisplatin and disease progression. We examined the relationships between DDH expression and chemotherapy resistance in ovarian cancer patients. Methods. Using immunohistochemistry, expression of DDH was measured in 41 patients with epithelial ovarian cancers. All patients underwent primary debulking surgery, followed with six cycles of cisplatin-based chemotherapy. Normal ovarian tissues were obtained from patients with benign gynecologic diseases (n = 14). Expression of DDH was confirmed by reverse transcription-polymerase chain reaction. The correlation between DDH expression and clinico-pathological parameters was analyzed by statistical analysis. Difference of progression-free survivals between different groups was compared by a log-rank test. Results. Eighteen ovarian cancer samples (43.9{\%}) expressed DDH at a moderate to strong level. This marked a significant difference from the negligible expression (1/14, 7.1{\%}) found in the control group (P = 0.02). Of interest, the clear cell adenocarcinoma revealed DDH overexpression (75{\%}) and mucinous adenocarcinoma revealed low DDH expression (16.7{\%}), although DDH expression did not show any significant variation according to different histotypes. DDH overexpression was found in a statistically significantly higher percentage of cisplatin-resistant cases (n = 8/11; 72.7{\%}) than in cisplatin-sensitive cases (n = 9/27; 33.3{\%}) (P = 0.037). Using multivariate analysis, only DDH retained as an independent role in predicting a poor chance of response to cisplatin-based treatment. DDH overexpression cases (median 12 months, 95{\%} confidence interval 4-20) demonstrated a shorter progression-free survival than DDH-negative cases (median 28 months, 95{\%} confidence interval 23-33), but this result did not reach the statistical significance (P = 0.1742). In the advance stage, the DDH-positive group has a shorter PFS as compared with DDH-negative group, and this result closely approaches the statistical significance (P = 0.0669). Conclusions. DDH is expressed in a high percentage of primary ovarian tumors and its expression may be associated with cisplatin-based chemotherapy resistance. The possible prognostic role of DDH in ovarian carcinoma deserves further study.",
keywords = "Chemotherapy resistance, Dihydrodiol dehydrogenase (DDH), Ovarian cancer",
author = "Chen, {Yi Jen} and Yuan, {Chiou Chung} and Chow, {Kuan Chih} and Wang, {Peng Hui} and Lai, {Chiung Ru} and Yen, {Ming Shyen} and Wang, {Liang Shun}",
year = "2005",
month = "4",
doi = "10.1016/j.ygyno.2004.12.031",
language = "English",
volume = "97",
pages = "110--117",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients

AU - Chen, Yi Jen

AU - Yuan, Chiou Chung

AU - Chow, Kuan Chih

AU - Wang, Peng Hui

AU - Lai, Chiung Ru

AU - Yen, Ming Shyen

AU - Wang, Liang Shun

PY - 2005/4

Y1 - 2005/4

N2 - Objective. Results of a recent study on human ovarian cancer cell lines indicated that overexpression of dihydrodiol dehydrogenase (DDH) was associated with resistance to cisplatin and disease progression. We examined the relationships between DDH expression and chemotherapy resistance in ovarian cancer patients. Methods. Using immunohistochemistry, expression of DDH was measured in 41 patients with epithelial ovarian cancers. All patients underwent primary debulking surgery, followed with six cycles of cisplatin-based chemotherapy. Normal ovarian tissues were obtained from patients with benign gynecologic diseases (n = 14). Expression of DDH was confirmed by reverse transcription-polymerase chain reaction. The correlation between DDH expression and clinico-pathological parameters was analyzed by statistical analysis. Difference of progression-free survivals between different groups was compared by a log-rank test. Results. Eighteen ovarian cancer samples (43.9%) expressed DDH at a moderate to strong level. This marked a significant difference from the negligible expression (1/14, 7.1%) found in the control group (P = 0.02). Of interest, the clear cell adenocarcinoma revealed DDH overexpression (75%) and mucinous adenocarcinoma revealed low DDH expression (16.7%), although DDH expression did not show any significant variation according to different histotypes. DDH overexpression was found in a statistically significantly higher percentage of cisplatin-resistant cases (n = 8/11; 72.7%) than in cisplatin-sensitive cases (n = 9/27; 33.3%) (P = 0.037). Using multivariate analysis, only DDH retained as an independent role in predicting a poor chance of response to cisplatin-based treatment. DDH overexpression cases (median 12 months, 95% confidence interval 4-20) demonstrated a shorter progression-free survival than DDH-negative cases (median 28 months, 95% confidence interval 23-33), but this result did not reach the statistical significance (P = 0.1742). In the advance stage, the DDH-positive group has a shorter PFS as compared with DDH-negative group, and this result closely approaches the statistical significance (P = 0.0669). Conclusions. DDH is expressed in a high percentage of primary ovarian tumors and its expression may be associated with cisplatin-based chemotherapy resistance. The possible prognostic role of DDH in ovarian carcinoma deserves further study.

AB - Objective. Results of a recent study on human ovarian cancer cell lines indicated that overexpression of dihydrodiol dehydrogenase (DDH) was associated with resistance to cisplatin and disease progression. We examined the relationships between DDH expression and chemotherapy resistance in ovarian cancer patients. Methods. Using immunohistochemistry, expression of DDH was measured in 41 patients with epithelial ovarian cancers. All patients underwent primary debulking surgery, followed with six cycles of cisplatin-based chemotherapy. Normal ovarian tissues were obtained from patients with benign gynecologic diseases (n = 14). Expression of DDH was confirmed by reverse transcription-polymerase chain reaction. The correlation between DDH expression and clinico-pathological parameters was analyzed by statistical analysis. Difference of progression-free survivals between different groups was compared by a log-rank test. Results. Eighteen ovarian cancer samples (43.9%) expressed DDH at a moderate to strong level. This marked a significant difference from the negligible expression (1/14, 7.1%) found in the control group (P = 0.02). Of interest, the clear cell adenocarcinoma revealed DDH overexpression (75%) and mucinous adenocarcinoma revealed low DDH expression (16.7%), although DDH expression did not show any significant variation according to different histotypes. DDH overexpression was found in a statistically significantly higher percentage of cisplatin-resistant cases (n = 8/11; 72.7%) than in cisplatin-sensitive cases (n = 9/27; 33.3%) (P = 0.037). Using multivariate analysis, only DDH retained as an independent role in predicting a poor chance of response to cisplatin-based treatment. DDH overexpression cases (median 12 months, 95% confidence interval 4-20) demonstrated a shorter progression-free survival than DDH-negative cases (median 28 months, 95% confidence interval 23-33), but this result did not reach the statistical significance (P = 0.1742). In the advance stage, the DDH-positive group has a shorter PFS as compared with DDH-negative group, and this result closely approaches the statistical significance (P = 0.0669). Conclusions. DDH is expressed in a high percentage of primary ovarian tumors and its expression may be associated with cisplatin-based chemotherapy resistance. The possible prognostic role of DDH in ovarian carcinoma deserves further study.

KW - Chemotherapy resistance

KW - Dihydrodiol dehydrogenase (DDH)

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=15544379141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15544379141&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2004.12.031

DO - 10.1016/j.ygyno.2004.12.031

M3 - Article

C2 - 15790446

AN - SCOPUS:15544379141

VL - 97

SP - 110

EP - 117

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -